glp-1 for diabetes Glucagon-like peptide-1 GLP-1 Drugs and Type 1

Furthermore, GLP-1 has the ability to decrease gastric acid secretion and postprandial gastric emptying, limit gastric and duodenal peristalsis through vagus nerve inhibition, and raise pylorus pressure, all of which contribute to a decrease in appetite, weight loss, and the so-called "ileal braking" effect [121]

While Blue Cross Blue Shield may cover these medications under certain conditions, the cost can still be a barrier for some

Severe gastrointestinal disease, particularly gastroparesis, may alter both efficacy and tolerability and requires careful consideration

Compounded GLP-1 therapy carries the same safety profile as brand-name semaglutide because the active pharmaceutical ingredient is identical

Some products are refrigerated until use